Abstract 1446
Background
Lung cancer accounts for one-quarter of all cancer deaths around the world. The identification of novel biomarkers from blood to differentiate tumors from normal tissue and to predict tumor behavior and patients’ survival is of great importance in clinical practice. We aimed to establish a nomogram with patients’ characteristics and all available hematological biomarkers for lung cancer patients.
Methods
All indexes were cataloged according to clinical significance. Principle component analysis (PCA) was used to reduce the dimensions. Each component was transformed into categorical variables based on recognized cut-off values from receiver operating characteristic (ROC) curve. Kaplan-Meier analysis with log-rank test was used to evaluate the prognostic value of each component. Multivariate analysis was used to determine the promising prognostic biomarkers. Five components were entered into a predictive nomogram. The model was subjected to bootstrap internal validation and to external validation with a separate cohort from Shandong Cancer Hospital. The predictive accuracy and discriminative ability were measured by concordance index (C index) and risk group stratification.
Results
Two hundred and fourty-eight patients were retrospectively analyzed in this study, with 134 in the Discovery Group and 114 in the Validation Group. Forty-seven indexes were sorted into 8 subgroups, and 20 principle components were extracted for further survival analysis. Via cox regression analysis, five components were significant and entered into predictive nomograms. The calibration curves for probability of 3-, and 5-year overall survival (OS) showed optimal agreement between nomogram prediction and actual observation. The new scoring system according to nomogram allowed significant distinction between survival curves within respective tumor-node-metastasis (TNM) subgroups.
Conclusions
A nomogram based on the clinical indexes was established for survival prediction of lung cancer patients, which can be used for treatment therapy selection and clinical care option. PCA makes big data analysis feasible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract